Laronde: Laronde Announces New Leadership

Laronde, the company pioneering Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express proteins inside the body for breakthrough treatments – today announced that Pablo J. Cagnoni, M.D., will step down from his role as Chief Executive Officer effective May 26, 2023, to become President and Head of Research & Development of Incyte. Dr. Cagnoni will remain a member of Laronde’s Board of Directors. John Mendlein, Ph.D., the company’s Chairman, will become its interim Chief Executive Officer.